Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

U.S. Court of Federal Claims — Judicial Business 2024

The U.S. Court of Federal Claims has nationwide jurisdiction over a variety of monetary claims against the federal government, including those involving tax refunds, federal taking of private property for public use, pay and dismissal of federal civilian employees, pay and dismissal of military personnel, land claims brought by Native Americans and/or their tribe(s), contract disputes, bid protests, patents and copyright, congressional reference, and the National Vaccine Injury Compensation Act. Pursuant to 28 U.S.C. § 791(c), each January the clerk of court transmits to Congress a statement of all the judgments rendered, which notes the names of the claimants, the amounts, the dates of entry and nature of the claims, and the dispositions for all judgments rendered the previous fiscal year.

Filings in this court decreased 7 percent to 2,064 in 2024. Vaccine compensation cases rose 2 percent to 1,188. Excluding vaccine compensation cases, filings fell 16 percent to 876 as property taken cases dropped 83 percent to 61 cases filed. Many of the general jurisdiction cases were of increased complexity and national significance; for example, 11 percent of the general jurisdiction cases filed this fiscal year contained multiple plaintiffs, and 11 percent involved intervening parties.

Total case terminations climbed 15 percent to 2,377. Vaccine case terminations rose 16 percent to 1,491. Pending cases decreased 5 percent to 5,436.

Filings in 2024 were 10 percent higher than in 2020. Case filings under the National Vaccine Injury Compensation Act have fallen 1 percent from 1,197 petitions in 2020 to 1,188 petitions in 2024.

For data on filings in the Court of Federal Claims, see Tables G-2A and G-2B.